Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Therapeutic administration of peptides may result in anti‐drug antibody ( ADA ) formation, hypersensitivity adverse events ( AEs ) and reduced efficacy. As a large peptide, the immunogenicity of once‐weekly glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist dulaglutide is of considerable interest. The present study assessed the incidence of treatment‐emergent dulaglutide ADAs , hypersensitivity AEs , injection site reactions ( ISRs ), and glycaemic control in ADA ‐positive patients in nine phase II and phase III trials (dulaglutide, N = 4006; exenatide, N = 276; non‐ GLP ‐1 comparators, N = 1141). Treatment‐emergent dulaglutide ADAs were detected using a solid‐phase extraction acid dissociation binding assay. Neutralizing ADAs were detected using a cell‐based assay derived from human endothelial kidney cells ( HEK293 ). A total of 64 dulaglutide‐treated patients (1.6% of the population) tested ADA ‐positive versus eight (0.7%) from the non‐ GLP ‐1 comparator group. Of these 64 patients, 34 (0.9%) had dulaglutide‐neutralizing ADAs , 36 (0.9%) had native‐sequence GLP ‐1 ( nsGLP ‐1) cross‐reactive ADAs and four (0.1%) had nsGLP ‐1 neutralization ADAs . The incidence of hypersensitivity AEs and ISRs was similar in the dulaglutide versus placebo groups. No dulaglutide ADA ‐positive patient reported hypersensitivity AEs . Because of the low incidence of ADAs , it was not possible to establish their effect on glycaemic control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wysham, C., Blevins, T., Arakaki, R., Colon, G., Garcia, P., Atisso, C., Kuhstoss, D., & Lakshmanan, M. (2014) · Diabetes Care · doi:10.2337/dc13-2760 · Cited by 396
Nauck, M., Weinstock, R. S., Umpierrez, G. E., Guerci, B., Skrivanek, Z., & Milicevic, Z. (2014) · Diabetes Care · doi:10.2337/dc13-2761 · Cited by 284
Self-citationGiorgino, F., Benroubi, M., Sun, J.-H., Zimmermann, A. G., & Pechtner, V. (2015) · Diabetes Care · doi:10.2337/dc14-1625 · Cited by 268
Cited by
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394
Frias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321
“A recent trial reported development of anti-drug antibodies in 44.6% of patients receiving exenatide alone (Milicevic et al., 2016), a comparable proportion to the NNC00902746 group.”
ResultInfluentialMANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Semaglutide as a promising antiobesity drug
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019) · Obesity Reviews · doi:10.1111/obr.12839 · Cited by 159
“In contrast, the percentage of patients that developed antidrug antibodies was 9% for liraglutide, 3% for albiglutide, and 2% for dulaglutide.(39,40) Up to 4% of once‐weekly semaglutide‐treated patients developed antisemaglutide antibodies, while no cases of antisemaglutide antibodies were reported with once daily sem…”
BackgroundJendle, J., Grunberger, G., Blevins, T., Giorgino, F., Hietpas, R. T., & Botros, F. T. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2810 · Cited by 158
Metadata
- Authors
- Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., & Mace, K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-03-04
- Volume
- 18
- Issue
- 5
- Pages
- 533-536
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2335878298
- Cited by
- 32
- References
- 3
- FWCI
- 4.04
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide. https://app.cochat.ai/papers/10.1111/dom.12640
- The paper
- Milicevic, Z., Anglin, G., Harper, K., Konrad, R. J., Skrivanek, Z., Glaesner, W., Karanikas, C. A., & Mace, K. (2016). Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12640
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.